The commercial success of remdesivir, despite its narrow benefit for hospitalized coronavirus patients, highlights the lack of potent tools for doctors six months into the pandemic.
The commercial success of remdesivir, despite its narrow benefit for hospitalized coronavirus patients, highlights the lack of potent tools for doctors six months into the pandemic.